Verapamil: its potential for causing serious complications in patients with hypertrophic cardiomyopathy.
- 1 September 1981
- journal article
- research article
- Published by Wolters Kluwer Health in Circulation
- Vol. 64 (3), 437-441
- https://doi.org/10.1161/01.cir.64.3.437
Abstract
Verapamil is extremely effective in the treatment of patients with hypertrophic cardiomyopathy. However, the basic physiologic actions of the drug may lead to serious adverse effects. An appreciation of this and an understanding of when these adverse effects are most likely to occur will minimize the potential of verapamil to cause serious complications in patients with hypertrophic cardiomyopathy.This publication has 10 references indexed in Scilit:
- Effects of verapamil on left ventricular systolic function and diastolic filling in patients with hypertrophic cardiomyopathy.Circulation, 1981
- Experimental studies on the pathogenesis of asystole after verapamil in the dogThe American Journal of Cardiology, 1979
- Treatment of hypertrophic obstructive cardiomyopathy with verapamil.Heart, 1979
- VerapamilDrugs, 1978
- Regional contractility. Selective depression of ischemic myocardium by verapamil.Circulation, 1976
- Effects of intravenous verapamil on cardiac arrhythmias and on the electrocardiogramAmerican Heart Journal, 1975
- Electrophysiology and pharmacology of cardiac arrhythmias. VI. Cardiac effects of verapamilAmerican Heart Journal, 1975
- Haemodynamic effects of intravenous verapamil at rest and during exercise in subjectively healthy middle-aged menEuropean Journal of Clinical Pharmacology, 1975
- Asymmetric Septal HypertrophyAnnals of Internal Medicine, 1974
- Effect of verapamil on contractility, oxygen utilization, and calcium exchangeability in mammalian heart muscleCardiovascular Research, 1972